Get the app!
Back to Trades

Yocca Frank

Chief Scientific OfficerCIK 0001733272

Largest Purchase

No open-market purchases in the recent filings.

Profile

Filings
9
Buy transactions
0
Sell transactions
1
Companies
1
Active
2025–2026

Across 9 filings between 2025–2026, Yocca Frank, Chief Scientific Officer, has disclosed $7.4K in transactions — all concentrated in BioXcel Therapeutics, Inc. (BTAI). Their disclosed trades are heavily weighted toward selling$0 in buys and $7.4K in sells. Data is sourced from official SEC Form 3, 4, and 5 filings.

Trading History

9 loaded
Jun 17BTAI
BioXcel Therapeutics, Inc.
Yocca FrankChief Scientific OfficerExercise$0
May 22BTAI
BioXcel Therapeutics, Inc.
Yocca FrankChief Scientific OfficerSell$7.4K
May 7BTAI
BioXcel Therapeutics, Inc.
Yocca FrankChief Scientific OfficerExercise$0
Mar 16BTAI
BioXcel Therapeutics, Inc.
Yocca FrankChief Scientific OfficerExercise$0
Jan 5BTAI
BioXcel Therapeutics, Inc.
Yocca FrankChief Scientific OfficerAward$0
Dec 15BTAI
BioXcel Therapeutics, Inc.
Yocca FrankChief Scientific OfficerExercise$0
Sep 16BTAI
BioXcel Therapeutics, Inc.
Yocca FrankChief Scientific OfficerExercise$0
Aug 5BTAI
BioXcel Therapeutics, Inc.
Yocca FrankChief Scientific OfficerAward$0
Jul 22BTAI
BioXcel Therapeutics, Inc.
Yocca FrankChief Scientific OfficerGrant$0

9 filings